ADReCS

Pharmaceutical Information

Drug Name	Imatinib
Drug ID	BADD_D01136
Description	Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage	For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status	approved
ATC Code	L01EA01
DrugBank ID	DB00619
KEGG ID	D08066
MeSH ID	D000068877
PubChem ID	5291
TTD Drug ID	D0AZ3C
NDC Product Code	63850-4826; 68554-0034; 43598-345; 65162-795; 42292-044; 0378-2246; 43598-344; 51407-270; 0378-2245; 42292-043; 51407-269; 48087-0143; 65162-794
UNII	BKJ8M8G5HI
Synonyms	Imatinib Mesylate \| Mesylate, Imatinib \| Imatinib Methanesulfonate \| Methanesulfonate, Imatinib \| STI571 \| STI-571 \| STI 571 \| Gleevec \| Glivec \| ST 1571 \| ST1571 \| CGP 57148 \| CGP57148B \| CGP-57148 \| CGP57148 \| Imatinib \| Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide

Chemical Information

Molecular Formula	C29H31N7O
CAS Registry Number	152459-95-5
SMILES	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Abdominal mass	07.01.01.003	0.000168%		-
Acanthosis	23.01.04.003	0.000112%		-
Adenocarcinoma gastric	07.21.02.002; 16.13.03.002	0.000280%		-
Adenocarcinoma of colon	07.21.01.008; 16.13.01.010	0.000224%		-
Alopecia scarring	23.02.02.009	0.000168%		-
Atonic seizures	17.12.03.020	0.000112%		-
Bladder transitional cell carcinoma	16.08.01.002; 20.03.04.003	0.000336%		-
Blood blister	12.01.06.013; 23.03.01.028	0.001164%		-
Breast cancer recurrent	16.10.01.009; 21.05.01.017	0.000112%		-
Bronchial carcinoma	16.19.02.004; 22.08.01.015	0.000168%		-
Cervical cyst	16.04.05.002; 21.06.02.006	0.000112%		-
Chloroma	01.10.08.003; 16.01.08.003	0.000336%		-
Chordoma	15.09.03.013; 16.29.01.002	0.000951%		-
Chronic lymphocytic leukaemia refractory	01.10.06.004; 16.01.06.004	0.000112%		-
Chronic respiratory failure	14.01.04.005; 22.02.06.005	0.000224%		-
Colon cancer stage IV	07.21.01.012; 16.13.01.014	0.000112%		-
Concomitant disease aggravated	08.01.03.063	0.000526%		-
Hypergammaglobulinaemia benign monoclonal	01.14.01.004; 16.23.01.004	0.000112%		-
Leiomyosarcoma	15.09.03.016; 16.33.07.001	0.000112%		-
Lichen sclerosus	21.10.03.010; 23.03.08.006	0.000280%		-
Lung adenocarcinoma	16.19.01.002; 22.08.01.007	0.000280%		-
Metastases to adrenals	05.01.04.007; 16.22.02.012	0.000112%		-
Metastases to bone	15.09.03.006; 16.22.02.005	0.000672%		-
Metastases to kidney	16.22.02.017; 20.01.04.010	0.000168%		-
Metastases to lymph nodes	01.09.01.015; 16.22.02.006	0.000783%		-
Metastases to skin	16.22.02.023; 23.07.04.026	0.000168%		-
Neonatal respiratory distress syndrome	18.04.10.003; 22.11.02.010	0.000168%		-
Neuroblastoma	05.01.04.001; 16.30.03.002; 17.20.03.002	0.000224%		-
Normal newborn	18.08.06.001	0.000716%		-
Obstruction gastric	07.13.04.002	0.000112%

The 28th Page First Pre 28 29 30 31 32 Next Last Total 32 Pages